Gilead disclosed a partial clinical hold on two CAR-T cell therapy trials after several cases of ICANS (immune effector cell–associated neurotoxicity syndrome). The action halts or limits trial activity while regulators and the company review safety data. The disclosure highlights the ongoing intensity of neurotoxicity monitoring for CAR-T programs and the regulatory sensitivity to emerging event clusters. It also follows the field’s increasing emphasis on managing risk through protocol changes, supportive care algorithms, and patient selection refinements. In parallel, separate coverage in the feed pointed to a broader CAR-T oversight focus through multiple trial updates and FDA-related calendar moves, reflecting a tighter safety lens across cell therapy development. Companies and investigators typically respond to holds with protocol amendments and additional stratification or monitoring plans, but timing for resumption can vary based on regulatory review.